Understanding Glioblastoma Recurrence and Progression Through Blood and Tumor Samples
Official title: A Prospective Study to Better Understand the Molecular, Immune and Metabolic Mechanisms Involved in Glioblastoma Recurrence and Progression, in the Aim to Identify New Therapeutic Targets and to Improve Current Therapies
Run by University Hospital, Bordeaux · NCT07173829 · Data updated 2026-11-12
This study will test blood and tumor samples from adults with newly diagnosed or recurrent glioblastoma to explore the molecular and immune factors involved in tumor growth and relapse.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Drugs / interventions | immunotherapy, radiation |
| Locations | 1 site (Bordeaux) |
| Status | Recruiting |
| Started | October 22, 2025 |
| Main results expected | October 2031 |
| Study ends | October 2031 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT07173829 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older with suspected glioblastoma planned for surgical resection and who consent to genetic research.
✕Probably not a fit
Patients whose tumor biology does not reveal actionable targets or who do not receive experimental therapies may not benefit directly.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
BORDEAUX-GLIO is a prospective, single-center study that collects tumor tissue during surgery and blood samples to study the molecular, immune, and metabolic pathways driving glioblastoma progression and recurrence. Researchers will use transcriptomic and metabolomic analyses, including spatial approaches, and may generate γδT cells and patient-derived xenografts in preclinical models. The goal is to identify targets for new therapies and to develop potential radiosensitizing drugs and γδT cell-based immunotherapies for glioblastoma. The study emphasizes observational analyses and the generation of preclinical models to inform future treatments. Participation is limited to adults undergoing planned tumor resection who consent to genetic research.
Why it matters
Potential benefit: Findings could reveal new targets for therapies and help tailor future treatments for glioblastoma patients.
How similar studies have gone: Previous glioblastoma studies using multi-omics and immune analyses have provided insights, but this specific combination in a single-center setting is relatively novel in its scope.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery * Planned surgical tumor resection, * No objection to participate in research * Signed genetic consent Exclusion Criteria: * Patients under guardianship, curatorship or protective supervision * Taking immunosuppressants * Pregnant or breast-feeding women * Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care
Where it's running
-
CHU de Bordeaux
Bordeaux, France Recruiting
Study contacts
- Principal investigator: Julien ENGELHARDT, Dr — University Hospital, Bordeaux
- Study coordinator: Julien ENGELHARDT, Dr
- Email: julien.engelhardt@chu-bordeaux.fr
- Phone: 05 56 79 55 77
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Lixumistat window of opportunity in newly diagnosed glioblastoma
This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.
-
Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care
A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.
-
Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care
This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.
-
Maintenance radiotherapy after standard glioblastoma treatment
This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.